Investigational Drug Information for Serlopitant
✉ Email this page to a colleague
What is the development status for investigational drug Serlopitant?
Serlopitant is an investigational drug.
There have been 12 clinical trials for Serlopitant.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 29th 2018.
The most common disease conditions in clinical trials are Pruritus, Prurigo, and Neurodermatitis. The leading clinical trial sponsors are Menlo Therapeutics Inc., Vyne Therapeutics Inc., and Epidermolysis Bullosa Research Partnership.
There are twenty-one US patents protecting this investigational drug and eighty-three international patents.
Summary for Serlopitant
| US Patents | 21 |
| International Patents | 83 |
| US Patent Applications | 71 |
| WIPO Patent Applications | 55 |
| Japanese Patent Applications | 8 |
| Clinical Trial Progress | Phase 3 (2018-08-29) |
| Vendors | 26 |
Recent Clinical Trials for Serlopitant
| Title | Sponsor | Phase |
|---|---|---|
| A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa | Epidermolysis Bullosa Research Partnership | Phase 2 |
| A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa | Menlo Therapeutics | Phase 2 |
| A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa | Stanford University | Phase 2 |
Clinical Trial Summary for Serlopitant
Top disease conditions for Serlopitant
Top clinical trial sponsors for Serlopitant
US Patents for Serlopitant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Serlopitant | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Serlopitant | ⤷ Sign Up | ⤷ Sign Up | ||
| Serlopitant | ⤷ Sign Up | Use of NK-1 receptor antagonist serlopitant in pruritus | Menlo Therapeutics Inc. (Redwood, CA) | ⤷ Sign Up |
| Serlopitant | ⤷ Sign Up | Use of NK-1 receptor antagonist serlopitant in pruritus | MENLO THERAPEUTICS INC. (Redwood City, CA) | ⤷ Sign Up |
| Serlopitant | ⤷ Sign Up | Use of NK-1 receptor antagonists in pruritus | MENLO THERAPEUTICS INC. (Redwood City, CA) | ⤷ Sign Up |
| Serlopitant | ⤷ Sign Up | Hydroisoindoline tachykinin receptor antagonists | Merck & Co., Inc. (Rahway, NJ) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Serlopitant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Serlopitant | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Serlopitant | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Serlopitant | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Serlopitant | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| Serlopitant | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| Serlopitant | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
